**Supplementary Table: AQP4-IgG titer of specimens drawn at sequential time-points (pre-attack, attack, remission) in individual patients (transformed scale)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristic\*** | **# Pairs** | **# Samples** | **# People** | **Raw scale median**  **(IQR)** | **Estimated means†** | **Estimated mean differences (95% CI)†** | **P value** |
| **AQP4-IgG titer (log base-10 scale‡)** | | | | | | | |
| **Sample type** | 13 |  |  |  |  |  | **0.67** |
| Pre-attack |  | 12§ | 9 | 100,000 (10,000, 100,000) | 3.994 | 0.105 (-0.383, 0.593) |  |
| Subsequent attack |  | 10 | 9 | 10,000 (1,000, 100,000) | 3.889 | (reference) |  |
|  |  |  |  |  |  |  |  |
| **Sample type** | 18 |  |  |  |  |  | **0.28** |
| Pre-attack |  | 14§ | 11 | 10,000 (100, 100,000) | 3.177 | 0.272 (-0.207, 0.750) |  |
| Subsequent remission |  | 17 | 11 | 1,000 (100, 10,000) | 2.905 | (reference) |  |
|  |  |  |  |  |  |  |  |
| **Sample type** | 81 |  |  |  |  |  | **0.15** |
| Attack |  | 53 | 42 | 10,000 (1,000, 100,000) | 3.736 | 0.264 (-0.086, 0.615) |  |
| Subsequent remission |  | 71 | 42 | 10,000 (1,000, 100,000) | 3.472 | (reference) |  |
| **AQP4-IgG complement mediated cell killing titers (doubling scale\*\*)** | | | | | | | |
| **Sample type** | 9 |  |  |  |  |  | **0.06** |
| Pre-attack |  | 8§ | 7 | 640 (320, 1,280) | 6.143 | 0.714 (0.196, 1.233) |  |
| Subsequent attack |  | 8 | 7 | 240 (0, 960) | 5.429 | (reference) |  |
|  |  |  |  |  |  |  |  |
| **Sample type** | 21 |  |  |  |  |  | **0.72** |
| Pre-attack |  | 9§ | 7 | 160 (0, 320) | 3.611 | -0.222 (-1.446, 1.001) |  |
| Subsequent remission |  | 21 | 7 | 320 (10, 1,280) | 3.834 | (reference) |  |
|  |  |  |  |  |  |  |  |
| **Sample type** | 80 |  |  |  |  |  | **0.62** |
| Attack |  | 41 | 32 | 160 (20, 320) | 5.401 | 0.261 (-0.734, 1.256) |  |
| Subsequent remission |  | 73 | 32 | 160 (40, 640) | 5.140 | (reference) |  |

\*The data was limited to subsets of samples for individuals with samples collected at both time points within the same attack. For example, the first model was limited to pre-attack and subsequent attack samples which occurred during the same attack for the same patient. A pre-attack sample could be paired with multiple attack samples and vice versa.

†Estimates and p values were obtained from generalized estimating equation regression models which accounted for multiple samples within the same patient and attack number.

‡AQP4 end-titers for these models were transformed using log base 10, as follows: titer of 0 [transformed value 0]; 5 [0.70]; 10 [1]; 100 [2]; 1,000 [3], 10,000 [4], ≥100,000 [5].

§Includes one sample that could be classified as both pre-attack and attack (collected in between two attacks within a short timeframe) paired with another sample collected during the attack or remission phase of their later attack.

\*\*Complement values for these models were transformed using a doubling transformation as follows: titer of 0 [transformed value 0]; 5 [1]; 10 [2]; 20 [3]; 40 [4]; 80 [5]; 160 [6]; 320 [7]; 640 [8]; 1,280 [9]; 2,560 [10]; 5,120 [11]; 10,240 [12].

Abbreviation: AQP4; aquaporin-4, IQR; interquartile range.